Pharmacotherapy of Macular Diseases
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 20 February 2026 | Viewed by 52
Special Issue Editor
Interests: macular disorders; genetics; pharmacogenetics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Vascular endothelial growth factor (VEGF) plays a crucial role in retinal homeostasis and is a key factor in various macular diseases, including neovascular age-related macular degeneration, diabetic macular edema, and macular edema associated with retinal vein occlusion. It has been over 20 years since the first VEGF inhibitor (pegaptanib) was available. To date, the second-generation VEGF inhibitors, including brolucizumab, faricimab, and high-dose aflibercept, are widely used, and many retinal specialists treat these disorders using various treatment regimens.
This Special Issue focuses on the treatment of these disorders, not only VEGF inhibitors but also other drugs, including steroids, etc.
Dr. Yoichi Sakurada
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- VEGF inhibitors
- macular disorders
- neovascular age-related macular degeneration
- diabetic macular edema
- macular edema associated with retinal vein occlusion
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
